| Autor: |
Prozzi GR; Centro Universitario de Farmacología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Centro colaborador para el uso racional de los medicamentos OMS/OPS, Buenos Aires, Argentina. Email: grprozzi@gmail.com.; Instituto de Ciencias de la Salud, Universidad Nacional Arturo Jauretche, Buenos Aires, Argentina. Email: grprozzi@gmail.com., Cañás M; Centro Universitario de Farmacología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Centro colaborador para el uso racional de los medicamentos OMS/OPS, Buenos Aires, Argentina.; Federación Médica de la Provincia de Buenos Aires, Argentina., Urtasun MA; Centro Universitario de Farmacología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Centro colaborador para el uso racional de los medicamentos OMS/OPS, Buenos Aires, Argentina.; Federación Médica de la Provincia de Buenos Aires, Argentina., Buschiazzo HO; 1Centro Universitario de Farmacología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Centro colaborador para el uso racional de los medicamentos OMS/OPS, 3Federación Médica de la Provincia de Buenos Aires., Dorati CM; Centro Universitario de Farmacología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Centro colaborador para el uso racional de los medicamentos OMS/OPS, Buenos Aires, Argentina., Mordujovich-Buschiazzo P; Centro Universitario de Farmacología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Centro colaborador para el uso racional de los medicamentos OMS/OPS, Buenos Aires, Argentina. |
| Abstrakt: |
Non-steroidal anti-inflammatories (NSAIDs) are among the most commonly used drugs in clinical practice. They block cyclooxygenases (COX) enzymes, but the degree of inhibition of COX-1 and COX-2 varies between them. In general, NSAIDs are classified in selective COX-2 or coxibs and non-selective or traditional NSAIDs. Both the analgesic and antiinflammatory effects, as well as the cardiovascular adverse effects, depend on the COX-2 inhibition. This paper reviews the available evidence of the increased risk of thrombotic events for both coxibs and traditional NSAID. The prothrombotic effect could be due to the inhibition of endothelial COX-2, with a decrease in production of prostacyclin and a relative increase in platelet thromboxane levels. Coxibs and diclofenac 150 mg/day seem to increase the risk of major vascular events by more than a third. Ibuprofen 2400 mg/day could slightly increase the risk of coronary events. Naproxen 1000 mg/day apparently does not increase the risk of vascular events. Besides ibuprofen and naproxen have the potential to decrease the cardioprotective effect of low doses of aspirin. Naproxen (= 1000 mg/day) and low doses of ibuprofen (= 1200 mg/day) are considered to have the most favorable thrombotic cardiovascular safety profiles of all NSAIDs. Therapeutic decisions should be based on an assessment of a person's individual risk factors, using the safest NSAIDs, at the lowest effective doses, for the shortest duration necessary to control symptoms, restricting their use in patients with increased cardiovascular risk. |
